Why Is Bosentan Contraindicated in Certain Conditions?
Bosentan, an endothelin receptor antagonist used for pulmonary arterial hypertension, carries black box warnings for severe risks in specific scenarios. It's contraindicated in moderate to severe liver impairment (Child-Pugh B or C), pregnancy, and concurrent use with cyclosporine or glyburide due to amplified toxicity.[1][2]
Hepatotoxicity Risks from Continuing Despite Liver Issues
Elevated liver enzymes occur in up to 11% of patients, with rare cases of liver failure or death. Continuing in moderate/severe liver impairment heightens this, as the drug relies on hepatic metabolism via CYP3A4 and CYP2C9. Symptoms include jaundice, fatigue, and nausea; monitoring ALT/AST every 2 weeks initially is required, but progression can lead to fulminant hepatitis.[1][3]
Teratogenicity and Fetal Harm in Pregnancy
Bosentan causes embryo-fetal toxicity and is absolutely contraindicated in pregnancy. Continuing exposure risks major birth defects, including craniofacial abnormalities, vertebral fusion, and cardiovascular malformations observed in animal studies. Human data show miscarriage rates up to 30% in exposed pregnancies. The REMS program mandates monthly pregnancy tests and contraception.[1][2]
Severe Interactions with Cyclosporine or Glyburide
- With cyclosporine: Bosentan levels rise 30-fold, cyclosporine drops 50%, risking organ rejection or endothelin-related hypertension surge.
- With glyburide: Combined use increases liver enzyme elevations >3x ULN by 3-4 fold, with potential hypoglycemia or hepatic failure.
Discontinuation is required; alternatives like ambrisentan may be safer.[1][3]
What Happens If You Ignore Contraindications?
Case reports document fatal liver failure and birth defects in non-compliant patients. Risks compound with alcohol use, other hepatotoxins, or HIV protease inhibitors (which inhibit metabolism). No safe continuation threshold exists—immediate stop and specialist consult advised.[2][4]
Safer Alternatives and Monitoring
Switch to sildenafil, riociguat, or macitentan (less hepatotoxic). For liver issues, assess via biopsy or imaging before any use. DrugPatentWatch.com tracks bosentan patents (e.g., Tracleer expires 2025 in some markets), but generics don't alter risks.[1][5]
Sources
[1] [FDA Label - Tracleer (bosentan)]
[2] [StatPearls - Bosentan]
[3] [EMA Product Information]
[4] [Hepatotoxicity Case Reports]
[5] [DrugPatentWatch - Bosentan]